

C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2021

<https://marketpublishers.com/r/C10722F9DC40EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: C10722F9DC40EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in C-Met Mutated Non-small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Understanding

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Overview

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) is characterized by over-expression of C-Met tyrosine kinase receptor which is normally expressed by epithelial cells. C-Met stimulation induces phosphorylation of some specific tyrosine residues such as (Y1003-Y1313-Y1230/1234/1235-Y1349-Y1365) thereby activating multiple downstream signaling pathways including RAS/ERK, PI3K/AKT, and cSRC kinase pathways. Owing to SRC activation, C-Met is considered as an epithelial-mesenchymal transition promoter which induces high level of HGF (Hepatocyte growth factor) and

intra-tumoral C-Met expression that have been associated with the biology and prognosis in NSCLC. NSCLC is predominantly of three types based on the morphology of cancerous cells and these are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma. Smoking, being exposed to radiations, asbestos, and various chemicals such as arsenic, chromium, and others are the major risk factors for non-small cell lung cancer.

“C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape is provided which includes the disease overview and C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) treatment guidelines. The assessment part of the report embraces, in depth C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve C-Met Mutated Non-Small Cell Lung Cancer (NSCLC).

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Emerging Drugs Chapters

This segment of the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Emerging Drugs

EGF-816 (Nazartinib): Novartis Oncology

Novartis's lead drug candidate, EGF-816 (Nazartinib), is a small molecule in combination with INC280 in development for the treatment of non-small cell lung cancer. Clinical trials data demonstrated that EGF-816 (Nazartinib) for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) has beneficial effects. The drug is a new molecule which is an epidermal growth factor receptor antagonist that blocks the function of protein EGFR.

APL 101 (Bozitinib): Apollomics Inc.

Apollomics drug APL 101 (Bozitinib) is an orally administered small molecule currently being evaluated for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and has demonstrated good safety and efficacy profile in phase II trials. APL 101 (Bozitinib) is an anti-neoplastics which inhibits the C-met protein.

Further product details are provided in the report.....

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Therapeutic Assessment

This segment of the report provides insights about the different C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in C-Met Mutated Non-small Cell Lung Cancer (NSCLC)

There are approx. 5+ key companies which are developing the therapies for C-Met Mutated Non-small Cell Lung Cancer (NSCLC). The companies which have their C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drug candidates in the mid to advanced stage, i.e. phase III include, Novartis Oncology and others.

Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II and Phase I/II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Subcutaneous

Intravenous

Oral

Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

Small molecules

Natural metabolites

Monoclonal antibodies

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

C-Met Mutated Non-small Cell Lung Cancer (NSCLC): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs.

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Report Insights

- C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline Analysis

 - Therapeutic Assessment

 - Unmet Needs

 - Impact of Drugs

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing C-Met Mutated Non-Small Cell Lung

Cancer (NSCLC) drugs?

How many C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Novartis

Apollomics Inc.

Abbvie

Janssen Research and Development

Key Products

EGF-816 (Nazartinib)

APL 101 (Bozitinib)

Telisotuzumab Vedotin

JNJ-6118637

Contents

Introduction

Executive Summary

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) companies' collaborations, Licensing, Acquisition -Deal Value Trends

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

EGF 816 (Nazartinib): Novartis

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

APL 101 (Bozitinib): Apollomics Inc.

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
 Comparative Analysis
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report.....
Inactive Products
 Comparative Analysis
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Products
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Unmet Needs
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Market Drivers and Barriers
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Future Perspectives and
Conclusion
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Analyst Views
C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: C-Met Mutated Non-small Cell Lung Cancer (NSCLC) - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C10722F9DC40EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C10722F9DC40EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970